Regulatory status & access / Research-only
MOTS-c legal status, FDA 503A category, and compounding access
Access is under active FDA review and may expand in 2026 — anchored to one fact: MOTS-c is named on the FDA Pharmacy Compounding Advisory Committee agenda for July 23-24, 2026. A scheduled evaluation, not a decision.
The short version
Here is the MOTS-c legal status in plain terms. MOTS-c is not an FDA-approved drug for anything, and it is not a dietary supplement; it is sold only as a research chemical for laboratory use. The forward-looking part: the FDA is actively reviewing whether certain peptides can be used in pharmacy compounding, and MOTS-c is specifically named on the agenda of an FDA advisory-committee meeting set for July 23-24, 2026. That meeting is a scheduled discussion — a step in evaluation. It is not a decision, not a reclassification, and not a change to today's status. Nothing below is medical or legal advice, and this site sells nothing.
Current status: research peptide, not FDA-approved
MOTS-c — a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region — is a research peptide and is not an FDA-approved drug for any indication [16]. Under the U.S. Federal Food, Drug, and Cosmetic Act, a bulk drug substance (an active ingredient used as a starting material, rather than a finished approved drug) may be used in 503A pharmacy compounding only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [16]. Substances not yet on that list are evaluated by FDA through a public nomination process, informed by the Pharmacy Compounding Advisory Committee (PCAC) [16].
MOTS-c is one of the bulk drug substances FDA has scheduled for PCAC evaluation [18]. Being under evaluation is not the same as being on the bulks list or approved for compounding. The published FDA materials that establish a numbered 503A safety category do so for other specific peptides; this digest does not assign MOTS-c a 503A Category, because FDA's audited record places it in evaluation, not in a numbered category [16][18].
Under active review: the July 23-24, 2026 PCAC agenda
The momentum is real, and it is anchored to a single verifiable fact: MOTS-c is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" [18]. FDA's calendar lists it for evaluation in both free-base and acetate forms, and the same agenda lists BPC-157, TB-500, and KPV [18].
That is a scheduled evaluation and discussion only. A PCAC discussion is advisory; it is not a listing decision, not a reclassification, and not a change in MOTS-c's current status [18]. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by PCAC — being discussed by the committee is a step in evaluation, not the outcome [16]. The outcome of the July 2026 meeting is unknown and is not assumed here. This page states present-tense facts and cites FDA; it does not assert any future FDA action as already done, dated, or certain.
How legally compounded peptide access works
Compounding in the U.S. runs through two sections of the law. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and licensed physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered outsourcing facilities that compound larger batches under cGMP-style oversight [16].
The lawful access pathway is: a patient is evaluated by an appropriately licensed prescriber (in person or via a compliant telehealth encounter, which can serve as the front-end channel for the consultation); if appropriate and lawful, the prescriber issues a valid, patient-specific prescription; and the preparation is dispensed by a state-licensed 503A compounding pharmacy or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility [16]. Telehealth is a route to a licensed-prescriber consultation, not a separate legal status — it does not expand which substances may be compounded [16].
One ingredient-eligibility caveat governs all of this: the compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules, and a substance that FDA has flagged for significant safety risks (a Category 2 substance) is not eligible for routine 503A compounding while that status stands [16]. This is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply any substance.
Is MOTS-c a Supplement? Research-Only Status
Is MOTS-c a Supplement? Research-Only Status
MOTS-c is not a dietary supplement and is not an over-the-counter product. It has no FDA-approved indication, formulation, or dosing, and it is sold only as a research chemical for laboratory use [16]. Product purity, identity, and sterility vary by supplier and are not regulated as pharmaceuticals. This site is an editorial research digest: it describes the regulatory landscape and the published literature, and it does not sell, recommend, or supply MOTS-c or name any vendor.
Is MOTS-c legal?
MOTS-c is not an FDA-approved drug and is not a dietary supplement; it is sold only as a research chemical for laboratory use [16]. It is named on the FDA PCAC agenda for July 23-24, 2026 as a substance being considered for the 503A bulks list — a scheduled evaluation, not a change in current status [18].
What is the FDA 503A status of MOTS-c?
MOTS-c is not on the FDA 503A bulks list and is not an FDA-approved drug; it is scheduled for PCAC evaluation at the July 23-24, 2026 meeting [18]. A bulk substance may be used in 503A compounding only if it has a USP/NF monograph, is a component of an approved drug, or is on the bulks list — none of which currently applies to MOTS-c [16].
Can you get MOTS-c from a compounding pharmacy?
Legally compounded medicines require a valid, patient-specific prescription from a licensed prescriber, filled by a 503A pharmacy or 503B outsourcing facility, and the ingredient must be eligible under the bulk-substance rules [16]. MOTS-c is not on the 503A bulks list and is under FDA evaluation, so it is not eligible for routine 503A compounding while that status stands [16][18].